Promoter Shivalik Rasayan Limited has disclosed its shareholding in Medicamen Biotech Limited for the year ended March 31, 2026. The filing confirms that the promoter continues to hold a significant stake in the pharmaceutical company without creating any encumbrances on the shares during the financial year.

Shareholding Details

As per the disclosure submitted under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Shivalik Rasayan Limited holds 54,87,095 equity shares. This stake translates to 40.46% of the total equity share capital of Medicamen Biotech Limited as of March 31, 2026.

Encumbrance Status

The promoter explicitly stated that no encumbrance was created, directly or indirectly, on the held shares during the Financial Year 2025-26. This declaration provides clarity regarding the leverage-free status of the promoter's holding for the specified period.

The disclosure was filed by Rahul Bishnoi, Director of Shivalik Rasayan Limited, and submitted to the stock exchanges on April 7, 2026. Parul Choudhary, Company Secretary & Compliance Officer of Medicamen Biotech Limited, forwarded the disclosure to the exchanges.

Medicamen Biotech Limited reported a consolidated net profit of ₹979.64 lakh for the financial year ended March 31, 2026, compared to ₹655.57 lakh in the previous year. The company's total consolidated revenue for FY26 stood at ₹20,088.29 lakh, up from ₹16,879.10 lakh in FY25. The board of directors, meeting on May 27, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. These results were published in the Financial Express and Jansatta on May 28, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a consolidated net profit of ₹444.70 lakh on a total revenue of ₹6,238.18 lakh. In the standalone segment, the net profit for the year was ₹940.87 lakh on revenue of ₹18,195.01 lakh. The earnings per share (EPS) for the consolidated results increased to ₹7.22 for FY26 from ₹5.16 in the previous year.

Dividend Declaration

The board recommended a final dividend of ₹1.00 per equity share of the face value of ₹10 each for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting.

Auditor Appointments

M/s Rai Qimat & Associates, Statutory Auditors, issued an audit report with an unmodified opinion on the financial statements. Additionally, the board approved the appointment of M/s SPB & Co, Cost Accountants, as the Cost Auditor for FY26-27, and M/s Cheena & Associates as the Internal Auditor for the same period. The remuneration for the Cost Auditor is subject to ratification by shareholders.